Echocardiographic assessment of doxazosin on left ventricular mass in patients with essential hypertension.
A single daily dose of doxazosin taken during a 12-week period produced a significant reduction in blood pressure and left ventricular mass index in patients with mild or moderate hypertension. The systolic shortening coefficient was also increased and a trend in the improvement of ejection fraction, rate of circumferential fiber shortening, systolic contraction time, and preejective/ejective ratio was observed. No change in heart rate was recorded and no patients had side effects. The serum lipid profile was modified favorably, particularly with regard to the low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio. By producing a reduction in blood pressure and left ventricular mass while favorably modifying the serum lipid profile, doxazosin produced a beneficial change in the overall coronary heart disease risk profile.
Monsalve
P
P
Hypertension Unit, Hospital Universitario, Caracas, Venezuela.
Vera
O
O
Pérez Acuña
F
F
Medina
O
O
Ostojich
K
K
López
B
B
Torres
N
N
Lugo de Franco
V
V
Fonseca
R
R
D000959:Antihypertensive Agents / Q000627:therapeutic use*; D006332:Cardiomegaly / Q000000981:diagnostic imaging* / Q000188:drug therapy; D002784:Cholesterol / Q000097:blood; D003327:Coronary Disease / Q000453:epidemiology; D017292:Doxazosin; D004452:Echocardiography; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D011224:Prazosin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012307:Risk Factors; D014687:Venezuela / Q000453:epidemiology
D000959:Antihypertensive Agents; D008055:Lipids; D002784:Cholesterol; D017292:Doxazosin; D011224:Prazosin